Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Emergency department overcrowding in Canada: an update
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lonapegsomatropin (growth failure due to growth hormone deficiency, ≥ 3 to < 18 years)]
2023	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 856
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (breast cancer, adjuvant) - Addendum to Commission A22-89]
2023	NIHR Health Services and Delivery Research programme	Reducing unplanned hospital admissions from care homes: a systematic review
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. NICE technology appraisal guidance 857
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Maribavir (cytomegalovirus infection (treatment-refractory)) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Thermidas thermal imaging system
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivosidenib (cholangiocarcinoma with IDH1 R132 mutation, after at least 1 prior therapy)]
2023	National Institute for Health and Care Excellence (NICE)	Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 858
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Systemic therapy for children and adolescents as a psychotherapy method]
2023	Agency for Healthcare Research and Quality (AHRQ)	Measuring healthcare organization characteristics in cancer care delivery research
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Insertion of peripherally inserted central catheter with reservoir (PICC-port) in patients diagnosed with solid and hematological tumors with indication for chemotherapy]
2023	National Institute for Health and Care Excellence (NICE)	Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal). NICE technology appraisal guidance 859
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Latanoprost/netarsudil (glaucoma) - Benefit assessment according to §35a Social Code Book V]
2023	Norwegian Institute of Public Health (NIPH)	[Portable ECG equipment for the diagnosis of atrial fibrillation in the specialist health care: rapid HTA - scoping review]
2023	National Institute for Health and Care Excellence (NICE)	Maribavir for treating refractory cytomegalovirus infection after transplant. NICE technology appraisal guidance 860
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2023	NIHR Health Services and Delivery Research programme	Rapid evaluation of the Special Measures for Quality and challenged provider regimes: a mixed-methods study
2023	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating active non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 861
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (marginal zone lymphoma) - Benefit assessment according to §35a Social Code Book V]
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) - Benefit assessment according to §35a Social Code Book V]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (new therapeutic indication: obesity and control of hunger, Bardet-Biedl syndrome, ≥ 6 years)]
2023	National Institute for Health and Care Excellence (NICE)	Somatrogon for treating growth disturbance in children and young people aged 3 years and over. NICE technology appraisal guidance 863
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100]
2023	Agency for Healthcare Research and Quality (AHRQ)	Nonemergent percutaneous coronary intervention versus optimal medical treatment for stable ischemic heart disease: a rapid response literature review
2023	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted. NICE technology appraisal guidance 864
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V]
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. NICE technology appraisal guidance 865
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) - Benefit assessment according to § 35a SGB V]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic products for treatment of trauma-related osteomyelitis
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Talquetamab (multiple myeloma, at least 3 prior therapies)]
2023	National Institute for Health and Care Excellence (NICE)	Regorafenib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 866
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Benefit assessment according to §35a Social Code Book V]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline: B-cell acute lymphoblastic leukaemia (ALL), relapsed/ refractory, 0 ≤ 25 years)]
2023	National Institute for Health and Care Excellence (NICE)	Mitapivat for treating pyruvate kinase deficiency (terminated appraisal). NICE technology appraisal guidance 867
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sutimlimab (haemolytic anaemia in adult patients with cold agglutinin disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	NIHR Health Technology Assessment programme	Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline (diffuse large B-cell lymphoma, (DLBCL))]
2023	National Institute for Health and Care Excellence (NICE)	Vutrisiran for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 868
2023	The Danish Health Technology Council (DHTC)	[Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2023	Agency for Healthcare Research and Quality (AHRQ)	Nutrition as prevention for improved cancer health outcomes
2023	Health Information and Quality Authority (HIQA)	18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent prostate cancer: evidence synthesis to support a generic justification decision
2023	The Danish Health Technology Council (DHTC)	[High-tech hospital beds for use in intensive and neurological wards]
2023	National Institute for Health and Care Excellence (NICE)	Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Access routes of hysterectomy - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	National Institute for Health and Care Excellence (NICE)	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. NICE technology appraisal guidance 870
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Myomectomy versus no treatment - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Stereotactic virtual navigation systems for percutaneous tumour ablation]
2023	Agency for Healthcare Research and Quality (AHRQ)	Partial breast irradiation for breast cancer
2023	National Institute for Health and Care Excellence (NICE)	Eptinezumab for preventing migraine. NICE technology appraisal guidance 871
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[UAE and MRgFUS versus myoma enucleation - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	National Institute for Health and Care Excellence (NICE)	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 872
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of acute lower GI bleeding
2023	National Institute for Health and Care Excellence (NICE)	Cannabidiol for treating seizures caused by tuberous sclerosis complex. NICE technology appraisal guidance 873
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Interventions to prevent and reduce gang-related crime among children and young adults
2023	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: an update of the PTSD repository evidence base
2023	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. NICE technology appraisal guidance 874
2023	National Institute for Health and Care Excellence (NICE)	Semaglutide for managing overweight and obesity. NICE technology appraisal guidance 875
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: analysis of personal and clinical characteristics associated with a favourable response to psychosocial interventions aimed at preventing and treating common mental disorders and symptoms]
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 876
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: impact of physical activity on the adverse effects of cancer and cancer treatments in adults]
2023	Agency for Healthcare Research and Quality (AHRQ)	Postpartum care up to 1 year after pregnancy: a systematic review and meta-analysis
2023	National Institute for Health and Care Excellence (NICE)	Finerenone for treating chronic kidney disease in type 2 diabetes. NICE technology appraisal guidance 877
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: NK cell degranulation (natural killer)]
2023	National Institute for Health and Care Excellence (NICE)	Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. NICE technology appraisal guidance 878
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: NGAL assay for the detection of acute kidney injury]
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality for total knee replacement]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: osseointegration of bone-anchored prostheses in individuals living with lower limb amputation(s)]
2023	Ontario Health	Bariatric surgery for adults with class I obesity and difficult-to-manage type 2 diabetes
2023	National Institute for Health and Care Excellence (NICE)	Tezepelumab for treating severe asthma. NICE technology appraisal guidance 880
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[IV immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss]
2023	NIHR Health Technology Assessment programme	Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
2023	National Institute for Health and Care Excellence (NICE)	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Extracorporeal shock wave therapy for orthopaedic indications]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care in Austria. A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol
2023	NIHR Health Technology Assessment programme	Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023	National Institute for Health and Care Excellence (NICE)	Voclosporin with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 882
2023	National Institute for Health and Care Excellence (NICE)	Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Update PET/PET-CT evidence for need based planning in the area of oncology]
2023	Agency for Healthcare Research and Quality (AHRQ)	Radiation therapy for metastatic bone disease: effectiveness and harms
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence]
2023	National Institute for Health and Care Excellence (NICE)	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 883
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: principles and criteria for gene selection for the molecular diagnosis of constitutional genetic diseases by next-generation sequencing - Report in support of the deployment of the sequencing service]
2023	NIHR Health Technology Assessment programme	Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (beta-thalassaemia)]
2023	National Institute for Health and Care Excellence (NICE)	Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal). NICE technology appraisal guidance 884
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions - Part 2: Anorectal dysfunction, pelvic organ prolapse and perineal pain in women]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Sponsoring of patient initiatives in Austria. 5th update of the systematic analyses 2014 to 2019]
2023	NIHR Health and Social Care Delivery Program	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT